All the latest Form happenings. Want to stay in the loop? Subscribe Now
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Claire Aldridge, Chief Strategy Officer at Form Bio.
Form Bio’s Chief Strategy Officer, Claire Aldridge, is harnessing the new company’s computing power and bioinformatics to spur a genomic revolution.
New integration delivers 52% cost savings and 88% time savings in computational execution with gpu-accelerated industry-standard tools.
Innovative cell and gene therapies can potentially treat and cure some of the most debilitating diseases known to humankind. But moving preclinical candidates through development, manufacturing and regulatory approval presents some distinct difficulties compared to traditional drug development.
Spinout of George Church’s Colossal Biosciences launches with a ‘sweet spot’ for synthetic biology companies pursuing manufacturing, validation
Austin Day, PhD
March 22, 2023
Continuing our blog series on Transformer architectures and their use in gene therapy applications, we explore the latest variants’ size and speed improvements.
Nick Ketz, PhD
March 8, 2023
Transformer based architectures are uniquely efficient and powerful when used to process structured data. Read this blog to learn how they can be customized, adapted and applied to AAV construct optimization.
March 2, 2023
Leveraging large language models has proven to shorten the development time of gene therapies. Learn more here.
